Street View: Bristol Myers' pipeline milestones key to growth, say analysts

Bristol-Myers Squibb

30/10/2026 13:08

** Bristol ​Myers Squibb BMY.N raised its full-year revenue forecast on Thursday, citing strong sales of its newer medicines, but lowered its 2026 earnings per share projection due to a hefty acquisition-related charge
** 30 analysts rate the stock "buy" on average; median PT $64.5 - data compiled by LSEG
     
THE CATALYST IS IN THE LAB
** Truist Securities ("buy," PT: $70) says co faces near-term concerns over the launch of schizophrenia drug Cobenfy and mixed trial results for immune-mediated disease treatment admilparant, but upcoming study updates could provide important growth opportunities
** Jefferies ("buy," PT: $76) says key study updates for Cobenfy, blood thinner milvexian, autoimmune disease treatment Sotyktu, and cancer therapies CELMoDs are expected through early 2027, providing potential growth drivers for BMY
** Morgan Stanley ("underweight," PT: $40) says pipeline progress remains the key focus, with upcoming data for blood thinner milvexian in atrial fibrillation, an irregular heart rhythm, seen as the most important catalyst
** TD Cowen ("hold," PT: $70) says Cobenfy has seen slow patient uptake, while admilparant's data supports its potential, with progressive pulmonary fibrosis (PPF) seen as the bigger opportunity
     
     

 (Reporting by Akriti Shah in Bengaluru)
 ((akriti.shah@thomsonreuters.com ; X, formerly Twitter: @AkritiShahh))